Relypsa Reports Positive Top-Line Results for the First Part of Its Two-Part Pivotal Phase 3 Trial of Patiromer Redwood City, CA, September 10, 2013 – Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results on both the...
MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor Acquisition Expands Pipeline of Drug Candidates, Footprint in Hematologic Cancers San Diego – September 10, 2013 – MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the...
Catalyst Pharmaceutical Partners, Inc. Closes Previously Announced $15.1 Million Registered Direct Offering CORAL GABLES, Fla., Sept. 10, 2013 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today reported that it has closed its...
Oxford Immunotec Wins Place Again on The Sunday Times Hiscox Tech Track 100 Oxford, UK and Marlborough, MA; 18 September 2013 – Oxford Immunotec has been awarded a place on the prestigious Sunday Times Tech Track 100 league table for the second year running. Ranking...
Recent Comments